Twist Bioscience Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Twist Bioscience Corp Unternehmen

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Unternehmensinformationen

BörsenkürzelTWST

Name des UnternehmensTwist Bioscience Corp

IPO-datumOct 31, 2018

Gegründet am2013

CEODr. Emily M. Leproust, Ph.D.

Anzahl der mitarbeiter923

WertpapierartOrdinary Share

GeschäftsjahresendeOct 31

Addresse681 Gateway Blvd.

StadtSOUTH SAN FRANCISCO

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl94080

Telefon18007190671

Websitehttps://www.twistbioscience.com/

BörsenkürzelTWST

IPO-datumOct 31, 2018

Gegründet am2013

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Emily M. Leproust, Ph.D.

Chairman of the Board, Chief Executive Officer

343.35K

-0.63%

Mr. Patrick John Finn, Ph.D.

President, Chief Operating Officer

116.05K

-17.54%

Mr. Keith L. Crandell

Independent Director

92.71K

+5.07%

Mr. Dennis Cho

Chief Legal Officer and Corporate Secretary

50.48K

-0.51%

Ms. Paula Green

Senior Vice President - Human Resources

47.51K

-1.76%

Mr. Nelson C. Chan

Independent Director

22.25K

+25.16%

Dr. Melissa A. Starovasnik, Ph.D.

Independent Director

15.81K

+39.44%

Mr. Jan Johannessen

Independent Director

12.60K

+55.04%

Mr. Adam Laponis

Chief Financial Officer

10.70K

-8.04%

Mr. Robert Werner

Chief Accounting Officer, Vice President

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Emily M. Leproust, Ph.D.

Chairman of the Board, Chief Executive Officer

343.35K

-0.63%

Mr. Patrick John Finn, Ph.D.

President, Chief Operating Officer

116.05K

-17.54%

Mr. Keith L. Crandell

Independent Director

92.71K

+5.07%

Mr. Dennis Cho

Chief Legal Officer and Corporate Secretary

50.48K

-0.51%

Ms. Paula Green

Senior Vice President - Human Resources

47.51K

-1.76%

Mr. Nelson C. Chan

Independent Director

22.25K

+25.16%

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Apr 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

NGS tools

48.64M

54.83%

Synthetic genes

26.48M

29.85%

Antibody discovery

5.70M

6.42%

Oligo pools

5.09M

5.74%

DNA and Biopharma libraries

2.79M

3.15%

DNA libraries

2.79M

3.15%

Nach RegionUSD

Name

Umsatz

Anteil

Americas

53.71M

60.54%

EMEA

28.30M

31.91%

APAC

6.70M

7.55%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

NGS tools

48.64M

54.83%

Synthetic genes

26.48M

29.85%

Antibody discovery

5.70M

6.42%

Oligo pools

5.09M

5.74%

DNA and Biopharma libraries

2.79M

3.15%

DNA libraries

2.79M

3.15%

Aktionärsstatistik

Aktualisiert: Tue, May 20

Aktionäre

Aktionärstypen

Aktionäre

Anteil

ARK Investment Management LLC

10.42%

The Vanguard Group, Inc.

9.77%

Artisan Partners Limited Partnership

9.77%

BlackRock Institutional Trust Company, N.A.

7.73%

William Blair Investment Management, LLC

6.35%

Other

55.96%

Aktionäre

Anteil

ARK Investment Management LLC

10.42%

The Vanguard Group, Inc.

9.77%

Artisan Partners Limited Partnership

9.77%

BlackRock Institutional Trust Company, N.A.

7.73%

William Blair Investment Management, LLC

6.35%

Other

55.96%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

51.92%

Investment Advisor/Hedge Fund

49.22%

Hedge Fund

8.42%

Research Firm

3.10%

Individual Investor

1.98%

Pension Fund

1.42%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.27%

Family Office

0.24%

Institutionelle Beteiligung

Aktualisiert: Tue, Mar 4

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

565

67.44M

112.56%

-7.04M

2024Q4

578

67.47M

113.11%

-8.03M

2024Q3

588

67.80M

115.74%

-8.48M

2024Q2

579

66.59M

114.39%

-10.53M

2024Q1

565

68.18M

117.94%

-8.61M

2023Q4

559

67.81M

117.39%

-11.70M

2023Q3

560

68.09M

118.66%

-11.36M

2023Q2

577

69.42M

121.49%

-5.07M

2023Q1

593

64.77M

113.93%

-4.20M

2022Q4

610

60.52M

106.86%

-2.15M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

ARK Investment Management LLC

6.38M

10.7%

+786.30K

+14.05%

Feb 28, 2025

The Vanguard Group, Inc.

5.79M

9.71%

+189.79K

+3.39%

Dec 31, 2024

Artisan Partners Limited Partnership

5.89M

9.88%

-125.19K

-2.08%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

4.62M

7.75%

+119.93K

+2.66%

Dec 31, 2024

William Blair Investment Management, LLC

2.95M

4.95%

-527.57K

-15.17%

Dec 31, 2024

Invesco Advisers, Inc.

3.53M

5.92%

+25.56K

+0.73%

Dec 31, 2024

State Street Global Advisors (US)

2.54M

4.26%

-623.36K

-19.68%

Dec 31, 2024

Nikko Asset Management Co., Ltd.

2.61M

4.38%

-248.70K

-8.69%

Dec 31, 2024

Thrivent Asset Management, LLC

1.51M

2.52%

+532.04K

+54.64%

Dec 31, 2024

Verbundene ETFs

Aktualisiert: Fri, Jun 6

Name

Anteil

ARK Genomic Revolution ETF

6.34%

iShares Genomics Immunology and Healthcare ETF

2.62%

ARK Innovation ETF

2.1%

Global X Genomics & Biotechnology ETF

2.01%

WisdomTree BioRevolution Fund

1.82%

Franklin Genomic Advancements ETF

1.65%

ROBO Global Healthcare Technology & Innovation ETF

1.15%

BNY Mellon Innovators ETF

1.13%

Putnam Sustainable Future ETF

0.92%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.85%

ARK Genomic Revolution ETF

Anteil6.34%

iShares Genomics Immunology and Healthcare ETF

Anteil2.62%

ARK Innovation ETF

Anteil2.1%

Global X Genomics & Biotechnology ETF

Anteil2.01%

WisdomTree BioRevolution Fund

Anteil1.82%

Franklin Genomic Advancements ETF

Anteil1.65%

ROBO Global Healthcare Technology & Innovation ETF

Anteil1.15%

BNY Mellon Innovators ETF

Anteil1.13%

Putnam Sustainable Future ETF

Anteil0.92%

First Trust Nasdaq Lux Digi Health Solutions ETF

Anteil0.85%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

Twist Bioscience Corp

33.990USD

Twist Bioscience Corp

33.990

Übersicht

Unternehmen